Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P23786

UPID:
CPT2_HUMAN

ALTERNATIVE NAMES:
Carnitine palmitoyltransferase II

ALTERNATIVE UPACC:
P23786; B2R6S0; Q5SW68; Q9BQ26

BACKGROUND:
The enzyme Carnitine O-palmitoyltransferase 2, located in mitochondria, is essential for converting acylcarnitines back into acyl-CoA esters for beta-oxidation. This process is vital for energy production from long-chain fatty acids, with the enzyme active on C8-C18 acyl-CoA esters.

THERAPEUTIC SIGNIFICANCE:
Disruptions in Carnitine palmitoyltransferase II are linked to severe metabolic conditions, including stress-induced myopathy and lethal neonatal deficiency. Advancements in understanding this enzyme's role could pave the way for innovative treatments for these life-threatening diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.